semaj83/ctmatch_classification huggingface dataset:
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Uterine Fibroids Leiomyoma Premenopausal women, at least 18 years of age Diagnosis of uterine fibroid(s), confirmed by ultrasound History of menstrual cycles between 17 and 42 days Otherwise in good health Scheduled for a hysterectomy at the end of the treatment period Negative pregnancy test Agrees to double barrier method of contraception Pap test with no evidence of malignancy or pre-malignant changes Endometrial biopsy with no significant histological disorder  Less than 3 months after having a baby or breast-feeding Any abnormal lab or procedure result the study-doctor considers important Severe reaction(s) to or are currently using any hormone therapy History of cancer or alcohol or drug abuse Diagnosis of Polycystic Ovary Syndrome History of prolactinoma Current use of Intrauterine Device Significant gynecological disorder Uterine size > 32 weeks gestation Current diagnosis of endometriosis
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fibroid Uterus Leiomyoma Menorrhagia Metrorrhagia Uterine Fibroids Women that have completed 6 months of treatment in study C02-037 with no more than a 7-day interruption in their treatment Otherwise good health Premenopausal based on Estrogen and Follicle Stimulating Hormone levels Agrees to double-barrier method of contraception Adequate endometrial biopsy with no significant histological disorder  Any abnormal lab or procedure result(s) the study-doctor considers important History of a blood-clotting disorder Any prior surgical and/or invasive procedure(s) for uterine fibroids that resulted in either a cure or made the symptoms go away Significant gynecological disorder, such as endometrial polyp
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 20.0-50.0,  Trophoblastic Neoplasms Hydatidiform Mole Choriocarcinoma Gestational Trophoblastic Neoplasms  Unwilling to participate in the study
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Uterine Fibroids Pregnancy Subject with uterine fibroids, who desire pregnancy within 12 months and has the one of the following Women 20-40 age. Women age < 46 years old who plan to have egg donation. Women above 38 should test for normal ovarian function as judged by endocrinological evaluation If the couple has failed to conceive for more that 1 year, the woman should test for normal ovarian function as judged by endocrinological evaluation, and the male must have adequate sperm test Women undergoing fertility treatment or plan to have sperm donation Use or non use of non-steroidal treatments for excessive vaginal bleeding such as antifibrinolytic agents (e.g. Tranexamic acid) or non-steroidal anti-inflammatory drugs (e.g. Mefanamic Acid) has been maintained for the three months prior to the planned date of the study procedure and the patient has agreed to maintain this use or non-use through the 6-month follow-up period Clinically normal PAP smear within timing of National Guidelines in the country of the clinical site Able and willing to give consent and able to attend all study visits Able to communicate sensations during the MRgFUS procedure Having uterine fibroids that are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone) Tumor(s) are clearly visible on non-contrast MRI Largest fibroid 8 cm in diameter or 12 cm if receiving GnRH  Patient is pregnant as confirmed by pregnancy test at time of screening Uterine size >20 weeks as evaluated by US or MR Patients who are considered "high risk pregnancy" due to uterine factors (e.g. abnormal uterus, uterine scars, cerclage) except fibroids Patients with fibroid that is more than 50% sub-mucosal or with hysteroscopically resectable Patients with adenomyosis Patient is on dialysis Hematocrit is < 25 Patient has hemolytic anemia Patient has unstable cardiac status including: § Unstable angina pectoris on medication§ Documented myocardial infarction within 6 months of protocol entry§ Congestive heart failure requiring medication (other than diuretic)§ Currently taking anti-arrhythmic drugs§ Severe hypertension (diastolic BP>100 on medication)§ Presence of cardiac pacemaker Patient has an ASA score of >2
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Trophoblastic Neoplasms Uterine Neoplasms Hydatidiform Mole Choriocarcinoma Persistent or recurrent low risk Gestational Trophoblastic Tumor (GTT) WHO score 2-6 (re-evaluated at the time of relapse Histologically confirmed complete or partial moles on initial evacuation Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of pemetrexed All patients taking NSAIDs with longer half-lives, should interrupt dosing for at least 5 days before, the day of, and 2 days following pemetrexed administration Folic Acid (350-1000 micrograms) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy Vitamin B12 (1000 micrograms) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy  Previous treatment that included chemotherapy other than actinomycin -D or methotrexate (+/ folinic acid) Patients with more than 8 metastatic lesions identified Patients with metastases to liver, spleen, brain, kidney or GI tract
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Melanoma Male and female subjects above age 18 of any ethnicity will be enrolled in this study  Subjects will be excluded from the study if they have significant skin disease which would not allow manipulation of their photographs consistent with the rest of the subjects Since the study instructions are in English, Non-English speakers will be excluded Those with co-morbidity sufficiently severe to prevent them from being able to perform a SSE will be excluded In addition, those with cognitive impairment who are unable to give informed consent, or to understand the study instructions given to them, will be excluded
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Recurrent Herpes Labialis Patients aged 18 years or older A history typical for recurrent herpes labialis. The subject must have experienced three or more episodes of cold sores in the last 12 months, and have a history of prodromal symptoms, as defined by the patient, preceding at least 50% of these cold sores, and must also have a history of vesicular lesions in at least 50% of the recurrent episodes of cold sores General good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's account of his/her medical history Women of child bearing potential had to use an accepted method of birth control (surgical sterilization; intra-uterine contraceptive device; oral contraceptives; hormone delivery systems such as Norplant® or Depo-Provera injections; a diaphragm in combination with contraceptive cream, jelly, or foam; or a condom in combination with contraceptive cream, jelly or foam). Patients unable or unwilling to use one of the methods of birth control listed above for the duration of the study could not enter the study For women of child-bearing potential, a negative pregnancy test (urine) at screening was required Signature on the informed consent document  Previous herpes vaccination Patients using topical immunosuppressive agents (including steroids, tacrolimus and pimecrolimus) on or near the face or systemic immunosuppressive agents (including steroids, tacrolimus and pimecrolimus) within 30 days of screening Patients known to be immunosuppressed due to underlying disease (e.g. HIV infection) or concomitant treatment (e.g. cancer chemotherapy) Recent history of alcohol or drug abuse, which in the opinion of the investigator, could interfere with that study patient's compliance with study requirements Significant skin disease such as atopic dermatitis or eczema that would interfere with the assessment of lesions Allergy or hypersensitivity to formulations containing acyclovir, penciclovir, famciclovir, and/or other nucleoside analogues Women who were lactating or breast feeding Had already been randomized once into the study Patients who had received an investigational drug in the past four weeks
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Uterine Fibroids Menorrhagia and/or bulk symptoms associated with uterine fibroids  Malignancy Current or planned pregnancy Small submucous fibroids suitable for hysteroscopic resection Postmenopausal women Suspected or known adenomyosis Uterus size exceeding the umbilical level Contraindications against laparoscopic surgery
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 5.0-999.0,  Melanocytic Nevi Acquired Melanocytic Nevi Primary Cutaneous Melanoma Infants/Children Must be less than or equal to 5 years Must have large congenital melanocytic nevus (LCMN, diagnosed clinically or by biopsy) that is greater than 20 cm in any one dimension or that is greater than 8 cm in any one dimension involving the scalp Must have outside referring physician Adults Must be greater than 18 years Must have greater than or equal to 100 melanocytic nevi greater than 2 mm in diameter Must have at least one melanocytic nevus greater than or equal to 4 mm in longest dimension Can have prior history of cutaneous or ocular malignant melanoma Must have outside primary physician  The patient does not meet the criteria Diagnosis of genetic syndrome associated with multiple lentigines or nevi (Peutz-Jeghers syndrome, Carney complex, turner syndrome, Noonan's syndrome) Two or more first-degree relatives with history of cutaneous melanoma and familial atypical mole-melanoma syndrome phenotype Diagnosis of cancer-associated syndrome (xeroderma pigmentosum, type I neurofibromatosis, Li-Fraumeni syndrome) Inability to tolerate surgical procedure due to bleeding diathesis or disorder or other cause as determined by principal investigator Patient is unwilling to consider elective biopsy of a melanocytic nevus
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Uterine Leiomyomas Women included in the study must be at least 18 years if age, premenopausal, speak English, and have one or more uterine leiomyomas at least 2 cm in diameter and the utuerus must be enlarged to the size typical during the 8th week of pregnancy. Note that while the selcetion criteia are set to recruit women in which surgical intervention is a likely outcome, surgery is not a requirement for study inclusion  Women will be excluded if they are pregnant because of potential safety concerns associated with imaging and image contrast enhancements. If women become pregnant during the study, they wil have the option to stay in the study, but will have pelvic ultrasound scans in place of MRI scans Women who are taking or likely to start taking GnRH therapy will be excluded because this therapy, which is used as a treatment method for leiomyomas, sometmes induces their regression Women who are greater than 52 inches in circumference or greater than 350 pounds will be excluded because they will be too large to fit in the imaging equipment Women that have an intra-uterine device (IUD) will be excluded because these metal devices create 'shadowing' in MR images, making accurate measurement and interpretation of leiomyomas in the MRIs difficult Women are not excluded if they had a prior myomectomy, or if they are taking oral contraceptives The of only women of premenopausal age (greater than 18 years old) in this study is dictated by the nature of the condition
Patient description: A 36-year-old woman presents to the emergency department with 12 weeks of amenorrhea, vaginal spotting that has increased since yesterday, lower abdominal tenderness, nausea and vomiting. The physical exam reveals overall tender abdomen, 18-week sized uterus, and cervical dilation of 2 cm. The complete blood count and biochemical profile are normal. Point of care pregnancy test with cut-off sensitivity of 25 mIU/ml Beta-HCG is negative. The ultrasound reports enlarged uterus (12 cm x 9 cm x 7 cms) with multiple cystic areas in the interior. The differential diagnosis includes vesicular mole vs fibroid degeneration.

Clinical trial eligibility criteria: eligible ages (years): 30.0-50.0,  Leiomyoma Leiomyomatosis Uterine Neoplasms Patient chooses to participate and has signed informed consent Age between 30 and 50 years old Symptoms caused by uterine fibroids, such as heavy bleeding (menorrhagia) and/or bulk-related complaints such as urinary frequency, constipation or pelvic pain Patient has fibroids confirmed by MRI Patient has normal kidney function Patient is willing and able to undergo follow-up imaging at 3 and 6 months post UFE  Patients who are pregnant or plan to become pregnant within the study period, or desire future fertility Patients with a history of gynecologic malignancy Patients with known endometrial hyperplasia Patients with adenomyosis Patients with pelvic inflammatory disease Patients with Uteri < 250 ml (cm) calculated volume or > 24 weeks Patients with pedunculated subserosal fibroids with a narrow attachment (<50% diameter of the fibroid) to the uterus Patients with pelvic pain as dominant syndrome Known allergy to contrast media that cannot be adequately pre-medicated Patients not suitable for arterial access
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Healthy Movement Disorder Any volunteer of any age from birth to old age who is deemed medically fit to participate and is willing to provide their informed consent will be included in the study
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Laryngeal Disease Spastic Dysphonia Voice Disorder Symptoms present during speech and not apparent at rest Symptoms less evident during whisper, singing or falsetto Symptoms become worse with prolonged speaking, practice or anxiety Reflexive and emotional aspects of voice function are unaffected, such as coughing, laughter or crying  Any patient with a history of airway obstruction will be excluded from the study Structural abnormalities affecting the larynx such as vocal fold nodules, polyps, carcinoma, cysts, contact ulcers, or inflammation (laryngitis) Reduction in vocal fold movement range during non-speech tasks such as whistling which would suggest either paralysis or paresis, joint abnormality or neoplasm No smokers or tobacco users will be included in the study Subjects with history of a psychiatric disorder, under the care of a psychiatrist, or on medications for treatment of a psychiatric disorder will be excluded from the study. Examples of psychiatric disorders to be excluded are: somatoform disorders, conversion disorders, currently under treatment for a major depression, or a history of schizophrenia or a bipolar disorder. However, a history of a previous episode of a minor reactive depression would not a person from participation
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Essential Tremor Patients with essential tremor affecting the upper limbs who are 21 years of age or older Patients who are not taking medications for essential tremor or any other medical condition for at least 2 weeks Patients who have not consumed alcohol or cold medications containing alcohol for at least 24 hours prior to the day of the study Women must not be pregnant or lactating. Women of childbearing age must use birth control while participating in this study Patients must not have any neurological disease other than tremor (e.g., Parkinson's disease) Patients must not have evidence of thyroid, liver, kidney or chronic lung disease